期刊文献+

LGALS3BP 3’UTR荧光素酶报告基因载体构建及鉴定 被引量:1

Construction of a luciferase reporter gene vector for the LGALS3BP 3’UTR
下载PDF
导出
摘要 目的构建LGALS3BP(lectin,galactoside-binding,soluble,3 binding protein,LGALS3BP)基因3’非编码区(3’-untranslated region,3’UTR)的野生型及突变型荧光素酶报告基因重组载体并进行鉴定,以备进一步研究miRNA对LGALS3BP基因的调控。方法Targetscan软件预测LGALS3BP 3’UTR上的miRNA结合位点;以人肝癌细胞系SMMC-7721基因组DNA为模板,进行PCR扩增,获得野生型LGALS3BP基因3’UTR片段,经双酶切将目的片段定向插入报告基因载体pGL3-Control中,将克隆好的重组载体转化大肠埃希菌DH5α感受态细胞进行扩增,采用菌落PCR及测序监定重组子。设计位点突变型LGALS3BP 3’UTR扩增引物,以构建的野生型LGALS3BP 3’UTR重组质粒为模板,采用重叠PCR及定点突变PCR技术进行扩增分别构建单独位点及双位点突变型重组荧光素酶报告基因载体。结果野生型LGALS3BP 3’UTR重组质粒经菌落PCR鉴定,可见871 bp的目的基因片段,大小与预期相符;测序结果表明,插入序列与LGALS3BP 3’UTR序列完全一致且插入方向正确。Targetscan软件预测到LGALS3BP 3’UTR区有两个感兴趣的miRNA结合位点。突变型LGALS3BP 3’UTR重组质粒测序鉴定结果表明,单独位点及双位点突变型重组质粒中均成功引入结合位点突变。结论成功构建LGALS3BP的3’UTR野生型(pGL3-LGAL-W-3’UTR)、两个单独位点突变型(pGL3-LGAL-M1-3’UTR和pGL3-LGAL-M2-3’UTR)及双位点突变型(pGL3-LGAL-M-3’UTR)重组荧光素酶报告基因载体,为后续研究miRNA对LGALS3BP基因的调控奠定基础。 Objective To construct a recombinant luciferase reporter gene vector for wildtype and mutant 3’⁃untranslated regions(UTRs)of the LGALS3BP gene to study regulation of the LGALS3BP gene and miRNAs.Methods TargetScan was used to predict the binding site of miRNAs in the 3’UTR of the LGALS3BP gene.The wildtype LGALS3BP 3’UTR was amplified by PCR using genomic DNA from SMMC⁃7721 hepatocellular carcinoma cells as a template.PCR products were digested by two restriction enzymes and inserted into the luciferase reporter vector pGL3⁃control.Recombinant plasmids were verified by colony PCR and sequencing.Primers for LGALS3BP 3’UTR with binding site mutations were designed.Single and double site mutant luciferase reporter gene vectors were prepared by overlapping PCR and site⁃directed mutagenesis PCR using the wildtype LGALS3BP 3’UTR recombinant plasmid as a template.Results Colony PCR showed a target gene fragment of 871 bp,which was consistent with the expected size.The inserted sequence was consistent with the LGALS3BP 3’UTR in sequencing.TargetScan indicated two miRNA⁃binding sites in the LGALS3BP 3’UTR.The single and double site mutant sequences were successfully inserted into the LGALS3BP 3’UTR.Conclusions Wildtype LGALS3BP 3’UTR(pGL3⁃LGAL⁃W⁃3’UTR),two single site mutants(pGL3⁃LGAL⁃M1⁃3’UTR and pGL3⁃LGAL⁃M2⁃3’UTR),and a double site mutant(pGL3⁃LGAL⁃M⁃3’UTR)luciferase reporter gene vectors were successfully constructed,which may facilitate studies of LGALS3BP gene regulation through miRNAs.
作者 刘翠华 邓林林 赵方新 红梅 武建强 张烜 李奕君 温琪 郭冉 刘奕彤 马启豪 LIU Cuihua;DENG Linlin;ZHAO Fangxin;HONG Mei;WU Jianqiang;ZHANG Xuan;LI Yijun;WEN Qi;GUO Ran;LIU Yitong;MA Qihao(College of Basic Medicine,Inner Mongolia Medical University,Hohhot 010059,China;the First Clinical Medical College,Inner Mongolia Medical University,Hohhot 010059)
出处 《中国比较医学杂志》 CAS 北大核心 2023年第5期8-14,共7页 Chinese Journal of Comparative Medicine
基金 国家自然科学基金项目(81660482) 内蒙古医科大学2021年大学生科技创新“英才培育”项目(YCPY2021040) 内蒙古自治区卫生健康科技计划项目(202202128) 大学生创新创业训练计划项目(自治区级)(202210132020) 内蒙古自治区自然科学基金项目(2022MS08009)。
关键词 LGALS3BP 3’UTR 报告基因载体构建 定点突变 LGALS3BP 3’UTR reporter gene vector construction site⁃directed mutation
  • 相关文献

参考文献7

二级参考文献31

  • 1Jiao-Jiao Zhou,Shu Zheng,Li-Feng Sun,Lei Zheng.MicroRNA regulation network in colorectal cancer metastasis[J].World Journal of Biological Chemistry,2014,5(3):301-307. 被引量:7
  • 2Hubert E Blum.Hepatocellular carcinoma: Therapy and prevention[J].World Journal of Gastroenterology,2005,11(47):7391-7400. 被引量:28
  • 3Benazzi C, A1-Dissi A, Chau CH, et al. Angiogcncsis in sponta neous tumors and implications tor comparative tumor biology[ J ]. Sci World J, 2014,2014:919570.
  • 4Piccolo E, Tinari N, Semeraro D, et al. LGALS3BP, Lectin ga- lactoside-binding soluble 3 binding protein, induces vascular en- dothelial growth factor in human breast cancer cells and promotes angiogenesis[ J]. J Mol Med, 2013, 91 ( 1 ) : 83 - 94.
  • 5Martinez VG, Moestrup SK, Holmskov U, et al. The conserved scavenger receptor cysteine-rich supeffamily in therapy and diag- nosis[J]. Pharmacol Rev, 2011,63(4): 967-1000.
  • 6Tinari N, Lattanzio R, Querzoli P, et al. High expression of Mac2-BP (Mac-2 BP) is associated with poor survival in node- negative breast cancer patients not receiving adjuvant systemic therapies[J], lnt J Cancer, 2009, 124(2) : 333 -338.
  • 7Fornarini B, D'Ambrosio C, Natoli C, et al. Adhesion to Mac2- BP ( Mae-2 BP) as a mechanism for lymphoma drug resistance in vivo[J]. Blood, 2000, 96(9) : 3282 -3285.
  • 8Ozaki Y, Kontani K, Hanaoka J, et al. Expression and immuno- genicity of a tumor-associated antigen, Mae2-BP/Mac-2 binding protein, in lung carcinoma[ J1. Cancer, 2002, 95(9) : 1954 -1962.
  • 9Kashyap MK, Harsha HC, Renuse S, et al. SILAC-Based quan- titative proteomic approach to identify potential biomarkers from the esophageal squamous cell carcinoma secretome [ J 1. Cancer Biol Ther, 2010, 10(8) : 796 -810.
  • 10Srirajaskanthan R, Caplin ME, Waugh MG, et al. Identification of Mac-2-binding protein as a putative marker of neuroendocrine tumors from the analysis of cell line secretomes [ J 1- Mol Cell Proteom, 2010, 9(4) : 656 -666.

共引文献23

同被引文献3

引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部